Avalo Therapeutics (AVTX) Long-Term Debt Issuances (2022 - 2023)
Avalo Therapeutics' (AVTX) quarterly Long-Term Debt Issuances came in at $6.0 million in Q2 2023, down 60.0% YoY from $15.0 million in Q2 2022, and up 140.52% on a QoQ basis from -$14.8 million in Q4 2022.
Powered by 
Analysis
Avalo Therapeutics (AVTX) Long-Term Debt Issuances (2022 - 2023) Analysis & Trends
Avalo Therapeutics (AVTX) has 3 years of Long-Term Debt Issuances data on file, last reported at $6.0 million in Q2 2023.
- Quarterly Long-Term Debt Issuances fell 60.0% year-over-year to $6.0 million in Q2 2023, while the trailing twelve-month figure through Dec 2024 was $6.0 million (down 3.13% YoY) and the FY2023 annual result came in at $21.2 million, changed N/A from the prior year.
- Long-Term Debt Issuances rose to $6.0 million in Q2 2023, from -$14.8 million in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $15.0 million in Q2 2022 to a low of -$14.8 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Avalo Therapeutics | 843.26 Mn | 843.26 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 6.00 Mn |
| Dec 31, 2022 | -14.81 Mn |
| Jun 30, 2022 | 15.00 Mn |